Browsing Tag
drug development
13 posts
Can Atombeat and BioDuro’s trillion-compound AI engine transform peptide drug discovery in 2025?
Find out how Atombeat and BioDuro are using AI to revolutionize peptide drug discovery with faster timelines and lower R&D costs.
Triastek’s 3D-printed D23 tablet shows strong clinical results for IgAN treatment
Triastek has reported promising clinical results for its 3D-printed drug delivery product, D23 (Budesonide Ileum Targeted Tablets), which…
Granules India to acquire Senn Chemicals to expand CDMO business
Granules India Limited (BSE: 532482, NSE: GRANULES) has announced a strategic acquisition of Senn Chemicals AG, a Switzerland-based…
Cosette Pharmaceuticals to acquire Mayne Pharma in $430m deal, strengthening women’s health and dermatology portfolio
Cosette Pharmaceuticals has announced a definitive agreement to acquire Mayne Pharma Group Limited, a move that will significantly…
AbbVie reports 2024 financial results: Revenue growth driven by immunology and neuroscience
AbbVie (NYSE: ABBV) has released its full-year and fourth-quarter 2024 financial results, showing continued revenue growth despite challenges…
Could this startup have the cure for obesity? Meet Pep2Tango Therapeutics!
Versant Ventures has introduced Pep2Tango Therapeutics Inc., a biotechnology startup dedicated to pioneering next-generation therapies for weight loss.…
Amplia Therapeutics secures FDA fast track status for narmafotinib in pancreatic cancer, stock surges
Amplia Therapeutics Limited (ASX: ATX) has announced that its Focal Adhesion Kinase (FAK) inhibitor, narmafotinib, has been granted…
Terns Pharmaceuticals faces market pressure following stock offering announcement
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing small-molecule product candidates for serious diseases such as oncology and…
Quotient Sciences opens new $15m facility in Garnet Valley to boost drug development capabilities
Quotient Sciences, a UK-based drug development services provider, has inaugurated a new early phase formulation and manufacturing plant…
Taro Pharmaceutical ends licensing agreement with NovaBiotics over Novexatin failure
Taro Pharmaceutical Industries has terminated its licensing agreement with Scottish biotech company NovaBiotics concerning the Novexatin drug after…